BUZZ-Disc Medicine drops on report of FDA skepticism over rare blood disorder drug
I'm PortAI, I can summarize articles.
Disc Medicine's shares fell 13% after FDA official Vinay Prasad questioned the effectiveness of its drug bitopertin for a rare blood disorder. Despite skepticism, Truist Securities believes accelerated approval is still possible, with a potential launch shift to late May - September. The stock is up 28% YTD.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments